The effect of oleoylethanolamide supplementation on cardiometabolic factors: a systematic review and meta-analysis

This systematic review and meta-analysis of randomized controlled trials study sought to assess the effects of oleoylethanolamide (OEA) supplementation on many parameters related to cardiometabolic disorders. A thorough search was conducted across major databases using specific keywords to identify randomized controlled trials assessing the impact of OEA on cardiometabolic variables. The weighted mean difference (WMD) and 95% confidence intervals were calculated with a random-effects model. Data from 13 studies indicated substantial reductions in fasting blood sugar (WMD: -5.84 mg/dl), insulin (WMD: -3.26 µU/ml), waist circumference (WMD: -2.15 cm), triglycerides (WMD: -17.73 mg/dl), tumor necrosis factor-alpha (WMD: -2.44 pg/ml), and interleukin 6 (WMD: -0.87 pg/ml). An elevation in total antioxidant capacity (WMD: 0.43 mg/dl) was seen subsequent to OEA treatment. No substantial impacts were seen on other parameters. OEA supplementation, among other lifestyle variables, seems to provide significant improvements in certain cardiometabolic and oxidative stress-related indicators.